SOURCE-LINKED STUDY SUMMARY
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Abstract summarizedQuality not appraised
- What was studied
- Randomized comparison of semaglutide with placebo, tracking kidney failure, major kidney-function loss, or kidney-related or cardiovascular death.
- Who / model studied
- 3533 participants with type 2 diabetes and chronic kidney disease; median follow-up was 3.4 years.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- The primary outcome risk was 24% lower with semaglutide, with 331 versus 410 first events. Confirmatory secondary outcomes showed slower kidney-function decline, 18% lower cardiovascular-event risk and 20% lower death risk. Serious adverse events occurred in 49.6% versus 53.8%.
- Limitations & context
- The abstract reports an early-stop recommendation following a planned interim analysis.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa2403347